Article
Endocrinology & Metabolism
Lili Hu, Li Ma, Xinyi Xia, Tao Ying, Minzhi Zhou, Shuhua Zou, Haoyong Yu, Jun Yin
Summary: The study compared the efficacy of drug therapy and bariatric surgery for women with obesity and PCOS, finding that bariatric surgery was more effective in achieving complete remission of PCOS.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Jaime M. Moore, Stephanie W. Waldrop, Melanie Cree-Green
Summary: Recent studies have evaluated the effects of different weight loss strategies on hormonal, metabolic, and weight outcomes in individuals with polycystic ovary syndrome (PCOS). Calorie restriction remains a primary nutrition intervention for weight loss in PCOS patients, and a dietary macronutrient composition with lower glycemic carbohydrates may be more effective. Various types of physical activity have been shown to be effective in improving outcomes in PCOS patients and reducing weight.
CURRENT OBESITY REPORTS
(2021)
Review
Endocrinology & Metabolism
G. Pugliese, G. de Alteriis, G. Muscogiuri, L. Barrea, L. Verde, F. Zumbolo, A. Colao, S. Savastano
Summary: Despite the widespread agreement on the lack of pharmacological options for the treatment of Polycystic Ovary Syndrome (PCOS), studies have shown that GLP-1 receptor agonists (GLP-1RA) could be effective in managing the clinical manifestations of PCOS, including weight loss and insulin resistance. However, current studies primarily focus on PCOS patients with obesity, and more research is needed on the lean phenotype and higher doses of GLP-1RA. Furthermore, the potential effects of GLP-1 beyond weight loss still require further investigation, especially in PCOS patients without obesity.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Article
Endocrinology & Metabolism
Xuefeng Long, Hengwei Liu, Wenqian Xiong, Wenjin Li, Haitang He, Tian Fu, Xiaoou Li, Chunyan Chen, Ling Zhang, Yi Liu
Summary: This study aims to assess the efficacy of the combination of low dose of liraglutide and metformin in weight loss in Chinese Han women with PCOS. The results showed that this treatment significantly reduced body weight and BMI, with over 88.24% of participants losing more than 5% of their body weight. These findings suggest that the combination of low dose of liraglutide and metformin is effective in weight loss in Chinese Han women with PCOS.
GYNECOLOGICAL ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Qing Wen, Song Fang, Yanjing Liang, Yuting Tian, Yiding Chen, Jun Yuan, Qiu Chen
Summary: This study aimed to observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome. The results showed that the combined treatment was more effective in reducing weight, body mass index, waist circumference, and waist to height ratio compared to metformin monotherapy.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
D. Abdulkhalikova, A. Sustarsic, E. Vrtacnik Bokal, N. Jancar, M. Jensterle, T. Burnik Papler
Summary: This study aimed to investigate the effects of weight loss on the endometrium specific proteome, endocrine-metabolic characteristics, and motor capabilities of obese women with PCOS and infertility. The results showed increased protein abundance in certain proteins and decreased abundance in others in the endometrium after weight loss, as well as significant reductions in fasting blood glucose and free testosterone levels, and improvements in body composition and physical capacity.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Obstetrics & Gynecology
Iris Lee, Snigdha Alur-Gupta, Robert Gallop, Anuja Dokras
Summary: Women with polycystic ovary syndrome had lower gestational weight gain and lower likelihood of high weight retention at 6 weeks after delivery, but similar weight retention at 12 months after delivery compared with controls. The study suggests that the peripartum time period is important for weight management in high-risk groups like women with polycystic ovary syndrome.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Endocrinology & Metabolism
Josefin Kataoka, Ingrid Larsson, Eva Lindgren, Li Oskarson Kindstrand, Johanna Schmidt, Elisabet Stener-Victorin
Summary: The study investigated the circulating AMH levels in women with severe obesity and PCOS, as well as the effect of a one-year VLED weight loss program on AMH levels. The results showed that women with PCOS had higher AMH levels, but it couldn't accurately differentiate between women with PCOS and severe obesity. Additionally, significant weight loss did not impact AMH levels.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
David C. D. Hope, Matthew L. Vincent, Tricia M. M. Tan
Summary: Obesity and Type 2 diabetes are global health challenges, with potential treatment options such as co-agonists showing promise in improving efficacy and reducing adverse effects. Further research is needed to guide the safe, effective, and personalized use of GLP-1/glucagon co-agonists in targeting weight loss and metabolic disease in the future.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Nutrition & Dietetics
Federica Vinciguerra, Luigi Piazza, Carla Di Stefano, Claudia Degano, Alfredo Pulvirenti, Roberto Baratta, Lucia Frittitta
Summary: This study evaluated the efficacy of liraglutide treatment in patients who experienced poor response after bariatric surgery. The results showed that liraglutide was effective in promoting significant weight loss, improving body composition, and reducing the prevalence of metabolic syndrome in these patients.
FRONTIERS IN NUTRITION
(2023)
Review
Biochemistry & Molecular Biology
Mojca Jensterle, Rok Herman, Andrej Janez
Summary: Despite lifestyle intervention and symptomatic management being the main treatments for PCOS, GLP-1 receptor agonists have shown superior weight loss effects and additional metabolic, reproductive, and cardiovascular benefits compared to other treatments. However, concerns about contraception and washout periods before pregnancy have limited their acceptance in the clinical community treating PCOS.
Review
Medicine, General & Internal
Dan Tian, Wei Chen, Qing Xu, Xiaoyu Li, Qianzhou Lv
Summary: Liraglutide treatment significantly improves waist circumference, BMI, weight, and insulin resistance in obese women with PCOS, with a potential effect on FSH and LH but with high heterogeneity.
Article
Multidisciplinary Sciences
Frederico Perboyre Carioca Freitas, Carlos Ewerton Maia Rodrigues
Summary: This study found that treatment with liraglutide was effective in reducing weight and improving cardiometabolic and inflammatory parameters in obese patients with metabolic syndrome. Liraglutide treatment also significantly reduced trunk fat mass, which was strongly correlated with abdominal circumference.
SCIENTIFIC REPORTS
(2023)
Article
Obstetrics & Gynecology
Christiane Lundegaard Haas, Anette Varbo, Peter Norkjaer Laursen, Volker Schnecke, Adam H. Balen
Summary: This study examines the associations between baseline BMI and change in body weight with the likelihood of pregnancy in women with PCOS. The results show that higher baseline BMI is associated with a lower chance of pregnancy, while weight loss is associated with an increased chance of pregnancy. The findings suggest that weight loss is beneficial for overweight/obese women with PCOS who are seeking to become pregnant.
HUMAN REPRODUCTION
(2023)
Article
Pharmacology & Pharmacy
Anna Thorso Larsen, Morten A. Karsdal, Kim Henriksen
Summary: Long-acting dual amylin and calcitonin receptor agonists (DACRAs) have potential as treatments for obesity. Switching or combining treatment with KBP-336 and semaglutide improves weight loss and glucose tolerance in obese rats.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
